Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 021164
Company: FABRE KRAMER
Company: FABRE KRAMER
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
EXXUA | GEPIRONE HYDROCHLORIDE | EQ 18.2MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued | None | Yes | No |
EXXUA | GEPIRONE HYDROCHLORIDE | EQ 36.3MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued | None | Yes | No |
EXXUA | GEPIRONE HYDROCHLORIDE | EQ 54.5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued | None | Yes | No |
EXXUA | GEPIRONE HYDROCHLORIDE | EQ 72.6MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued | None | Yes | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
09/22/2023 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021164Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021164Orig1s000TOC.cfm |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
09/22/2023 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf |